2024
Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations
Jayakrishnan R, Kwiatkowski D, Rose M, Nassar A. Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations. The Oncologist 2024, 29: 833-841. PMID: 38907669, PMCID: PMC11449018, DOI: 10.1093/oncolo/oyae091.Peer-Reviewed Original ResearchMutational signaturesNon-small cell lung cancerBase substitutionsNon-small lung cancerCell lung cancerLung cancerSingle base substitutionsDoublet base substitutionsResponse to personalized treatmentGenomics effortsMutational signature analysisGenesis of cancerLoss of mismatch repairResponse to therapyMutational processesDamaged DNAAPOBEC activityMismatch repairRepair mechanismsTumor evolutionEndogenous processesMutationsPersonalized treatmentCancerTobacco smoke
2023
Time to Diagnosis and Treatment of Non-small Cell Lung Cancer in Patients Undergoing Lung Cancer Screening
Bernstein E, DeRycke E, Han L, Bastian L, Bade B, Lerz K, Kravetz J, Carino M, Rose M, Akgun K, Cain H. Time to Diagnosis and Treatment of Non-small Cell Lung Cancer in Patients Undergoing Lung Cancer Screening. 2023, a2734-a2734. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2734.Peer-Reviewed Original Research
2019
Multicenter phase II trial of RRx-001 in previously treated SCLC.
Morgensztern D, Rose M, Morris J, Ma P, Brzezniak C, Zeman K, Padmanabhan A, Hirth J, Spira A, Wong E, Padda S, Waqar S. Multicenter phase II trial of RRx-001 in previously treated SCLC. Journal Of Clinical Oncology 2019, 37: e20104-e20104. DOI: 10.1200/jco.2019.37.15_suppl.e20104.Peer-Reviewed Original ResearchSmall cell lung cancerRRx-001Partial responseStable diseaseOverall survivalPrior linesCommon treatment-emergent adverse eventsSingle-arm phase II studyArm phase II studyMulticenter phase II trialTreatment-emergent adverse eventsPhase II studyPhase II trialPlatinum-resistant diseaseCell lung cancerOverall response rateTreat populationII trialPrimary endpointAdverse eventsEtoposide chemotherapyII studyComplete responsePlatinum therapyLung cancer
2018
QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer.
Padda S, Brzezniak C, Waqar S, Wakelee H, Ma P, Rose M, Reid T, Spira A, Wong E, Zeman K, Oronsky B, Abrouk N, Morgensztern D. QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer. Journal Of Clinical Oncology 2018, 36: e20575-e20575. DOI: 10.1200/jco.2018.36.15_suppl.e20575.Peer-Reviewed Original Research
2012
Timeliness of care and stage at diagnosis of non-small cell lung cancer (NSCLC) with the implementation of a cancer care coordination program (CCCP) at a VA medical center.
Alsamarai S, Chao H, Yao X, Deng Y, Rose M. Timeliness of care and stage at diagnosis of non-small cell lung cancer (NSCLC) with the implementation of a cancer care coordination program (CCCP) at a VA medical center. Journal Of Clinical Oncology 2012, 30: 6033-6033. DOI: 10.1200/jco.2012.30.15_suppl.6033.Peer-Reviewed Original ResearchNon-small cell lung cancerTimeliness of careLung cancerEarly-stage lung cancerVeterans Affairs Connecticut Healthcare SystemPercent of patientsInitiation of therapyRetrospective cohort analysisCare coordination programCancer-related symptomsInitiation of treatmentCell lung cancerPrimary care providersStage lung cancerVA Medical CenterAbnormal imagingNSCLC careNSCLC patientsInitial imagingPatient satisfactionMean intervalMedical CenterCohort analysisAbnormal imagesCare providers